The average intra-assay variability expressed as CV Intra-assay for all samples (n = 184; control and CML samples included) was 10.5%. In addition, to monitor plate-to-plate variation, eight reference blood samples from healthy volunteers (age range 24-83 years) were included in each run. The resulting average CV Inter-assay for all eight reference samples was 15.3%.
Characteristics of healthy controls and patients are shown in Supplementary Material.
The 89 control individuals (unfilled circles, Figure 1a) showed the expected decline in TL with increasing age-a characteristic no longer detectable in CML patients (filled circles). Mean age adjusted TL (ΔT/S ratio) of CML patients was more spread within different age groups and significantly shorter (ΔT/S: − 0.3097 ± 0.6644, n = 95, Po0.001). This is in line with previous studies suggesting accelerated telomere shortening in CML mostly due to an increased turnover of the leukemic as opposed to the coexisting normal stem cell compartment (ref. 1, reviewed in ref. 7) . Of note, the analysis of ΔT/S versus age resulted in a positive correlation, indicating a more pronounced TL deficit in younger CML patients (P = 0.0017).
Although the existence of a substantial mean TL deficit in normal (Philadelphia chromosome negative) cells from patients with CML was excluded previously, 8 these data might either suggest a more pronounced proliferation rate of leukemic cells from younger in contrast to those from older CML patients, additional effects such as oxidative damage contributing more significantly to TL shortening in younger patients and/or an age-independent telomere threshold limiting the 'replicative telomere reserve' of BCR-ABL-positive stem cells in CML. Interestingly a similar telomere threshold has been observed in patients with hereditary and acquired aplastic anemia (ref. 9 , reviewed in ref. 10 ).
When we categorized T/S ratios into quartiles (Q1: 0.81 ± 0.13; Q2: 1.12 ± 0.08; Q3: 1.46 ± 0.12; Q4: 2.33 ± 0.52), median age did not differ significantly between the four quartiles ( Figure 1b Patients carrying the longest telomeres (Q4) seemed to have a lower risk profile compared with individuals with shorter TL. Sokal and Euro scores as continuous variable were significantly lower in Q4 as compared with Q2 and Q3 (Po0.01 for Sokal and Po0.05 for Euro score, Mann-Whitney U-test, Figures 2a and b) . Interestingly, only one single patient in Q4 was assigned to a Sokal high-risk category (out of 15 in all quartiles) and not a single patient had a high-risk Euro score (out of 7). In addition, when we analyzed individual prognostic parameters, longer telomeres (Q4) were accompanied by a significantly lower percentage of peripheral blast counts compared with Q1 (Po0.01, Mann-Whitney U-test, Figure 2c ). Consistent with previous retrospective studies in small patient cohorts, 2 these prospective study data point to a subset of CML patients at diagnosis who are characterized by the longest TL and the most favorable clinical prognostic score profile.
Next, we correlated TL with optimal molecular response to treatment according to European Leukemia Net (ELN) criteria 2013 13 during nilotinib first-line treatment (that is, BCR-ABL IS ⩽ 10% at 3 months, o1% at 6 months and ⩽ 0.1% (major molecular response (MMR)) at 12 months and later; Figure 2d ). After 3 months, as well as 6 months from start of therapy, no distinct differences within the patient quartiles could be detected. However, and as opposed to patients in Q1-Q3, all patients within Q4 reached MMR at 12 ( Figure 2d ) and 18 months (not shown, both Po0.05, Fisher's exact test). Long TL at diagnosis of CML-CP might therefore not only identify patients with favorable clinical prognostic scores but also predict response to nilotinib treatment in CML. However, long telomeres in Q4 were not positively correlated with the primary study endpoint, that is, a even superior response defined as MR4 (BCR-ABL IS o0.01%) at 18 months ( Figure 2d ). In summary, we could confirm that TL is significantly shortened in leukemic cells and no longer age dependent in CML patients at diagnosis. MM-qPCR allows TL measurement in stored DNA samples and can thus easily be incorporated into clinical trials involving molecular monitoring of BCR-ABL as study endpoints according to the ELN recommendations. 13 Nevertheless, quantitative fluorescence in situ and flow cytometry (flow FISH) based methodologies have been shown to be advantageous over MM-qPCR for TL measurements both with regard to accuracy of the measurements 14 and separation of myeloid from lymphoid cells in peripheral blood. 9 However, flow FISH requires viable peripheral blood or bone marrow cells sometimes complicating logistics of shipment.
TL measured in total leukocytes by MM-qPCR identifies a previously unrecognized CML patient subgroup with a relatively favorable outcome and may be predictive of response according to ELN criteria after 12 and 18 months of initial tyrosine kinase inhibitor therapy.
In conclusion and on validation in a larger study, TL could serve as a predictive biomarker in CML possibly identifying patients in early as opposed to later stages of chronic phase at diagnosis.
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